Cucurbitacin-E inhibits multiple cancer cells proliferation through attenuation of Wnt/β-catenin signaling

Cancer Biotherapy and Radiopharmaceuticals

Volumn 29, Issue 5, 2014, Pages 210-214

  Feng, Hui ^a   Zang, Li ^a   Zhao, Zhen Xia ^a   Kan, Quan Cheng ^b  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

cell proliferation; cucurbitacin E; Menin; Wnt catenin signaling

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CUCURBITACIN; CUCURBITACIN E; METHIONINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CTNNB1 PROTEIN, HUMAN; TRITERPENE; WNT PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; COLON CANCER; COLON POLYPOSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LUNG CANCER; LUNG CARCINOMA; MULTIPLE CANCER; PRIORITY JOURNAL; PROTEIN CONTENT; UPREGULATION; WNT SIGNALING PATHWAY; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; NEOPLASMS; TRITERPENES; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84902135778     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2014.1614     Document Type: Article

References (22)

1. Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 2012;12:849.
2. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13:83.
3. Rodon J, Dienstmann R, Serra V, et al. Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat Rev Clin Oncol 2013;10:143.
4. Patel MN, Halling-Brown MD, Tym JE, et al. Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 2013;12:35.
5. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer 2012; 12:159.
6. Albini A, Tosetti F, Li VW, et al. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 2012; 9:498.
7. Nelson LE, Valentine RJ, Cacicedo JM, et al. A novel inverse relationship between metformin-triggered AMPKSIRT1 signaling and p53 protein abundance in high glucose- exposed HepG2 cells. Am J Physiol Cell Physiol 2012; 303:C4.
8. Sarfstein R, Friedman Y, Attias-Geva Z, et al. Metformin downregulates the insulin/IGF-I signaling pathway and in- hibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One 2013;8:e61537.
9. Chen JC, Chiu MH, Nie RL, et al. Cucurbitacins and cucurbitane glycosides: Structures and biological activities. Nat Prod Rep 2005;22:386.
10. Chen X, Bao J, Guo J, et al. Biological activities and potential molecular targets of cucurbitacins: A focus on cancer. Anticancer Drugs 2012;23:777.
11. Ríos JL, Andújar I, Escandell JM, et al. Cucurbitacins as inducers of cell death and a rich source of potential anticancer compounds. Curr Pharm Des 2012;18:1663.
12. Lu P, Yu B, Xu J. Cucurbitacin B regulates immature myeloid cell differentiation and enhances antitumor immunity in patients with lung cancer. Cancer Biother Radiopharm 2012;27:495.
13. Duangmano S, Sae-Lim P, Suksamrarn A, et al. Cucurbitacin B causes increased radiation sensitivity of human breast cancer cells via G2/M cell cycle arrest. J Oncol 2012;2012:601682.
14. Ishii T, Kira N, Yoshida T, et al. Cucurbitacin D induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial and ovarian cancer cells. Tumour Biol 2013; 34:285.
15. Bienz M. The subcellular destinations of APC proteins. Nat Rev Mol Cell Biol 2002;3:328.
16. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489.
17. Zhang T, Li J, Dong Y, et al. Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Breast Cancer Res Treat 2012;135:445.
18. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009;10:468.
19. Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol 2012;13:767.
20. Agarwal SK. Multiple endocrine neoplasia type 1. Front Horm Res 2013;41:1.
21. Gaztambide S, Vazquez F, Castaño L. Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1). Minerva Endocrinol 2013;38:17.
22. Seigne C, Auret M, Treilleux I, et al. High incidence of mammary intraepithelial neoplasia development in Men1- disrupted murine mammary glands. J Pathol 2013;229:546.